So, if leronlimab reduced mortality 24% for critical patients (patients who are facing death) how would it be even possible for leronlimab to not work significantly for severe patients? I feel like there is more good news coming. In the m/m trial leronlimab showed it was reducing the progression to severe, so I doubt that fore some strange reason it does nothing for severe when it works for moderate and critical. I can only guess that the trial design may be a problem for showing this, however the data collected will show the MOA clearly. Nader gave us the most important readout, leronlimab saved many lives for the most sick patients. These are the patients that everything has been tried and were as close to death as you can get. Severe patients may recover, but they also may become critical. I feel strongly there were a lot of severe patients that did not become critical because of leronlimab.